Effects of Botulinum Toxin Type A on the Psychosocial Features of Myofascial Pain TMD Subjects: A Randomized Controlled Trial

Aims: To determine the effects of botulinum toxin type A (BoNT-A) on the psychosocial features of patients with masticatory myofascial pain (MFP). Methods: A total of 100 female subjects diagnosed with MFP were randomly assigned into five groups (n = 20 each): oral appliance (OA); saline solution (SS); and three groups with different doses of BoNT-A. Chronic pain-related disability and depressive and somatic symptoms were evaluated with the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD) Axis II instruments at baseline and after 6 months of treatment. Differences in treatment effects within and between groups were compared using chi-square test, and Characteristic Pain Intensity (CPI) was compared using two-way ANOVA. A 5% probability level was considered significant in all tests. Results: Most patients presented low pain-related disability (58%), and 6% presented severely limiting, high pain-related disability. Severe depressive and somatic symptoms were found in 61% and 65% of patients, respectively. In the within-group comparison,

BoNT-A and OA significantly improved (P < .001) scores of pain-related disability and depressive and somatic symptoms after 6 months. Only the scores for pain-

related disability changed significantly over time in the SS group. In the between-

group comparison, BoNT-A and OA significantly improved (P < .05) scores of all variables at the final follow-up when compared to the SS group. No significant difference was found between the BoNT-A and OA groups (P > .05) for all assessed variables over time. Conclusion: BoNT-A was at least as effective as OA in improving pain-related disability and depressive and somatic symptoms in patients with masticatory MFP.

botulinum toxin; depression; myofascial pain; psychosocial impairment; temporomandibular disorders

1. Dworkin SF, LeResche L. Research diagnostic criteria for temporomandibular disorders: Review, criteria, examinations and specifications, critique. J Craniomandib Disord 1992;6:301–355.

2. Manfredini D, Guarda-Nardini L, Winocur E, Piccotti F, Ahlberg J, Lobbezoo F. Research diagnostic criteria for temporomandibular disorders: A systematic review of axis I epidemiologic findings. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;112:453–462.

3. Raja SN, Carr DB, Cohen M, et al. The revised International Association for the Study of Pain definition of pain: Concepts, challenges, and compromises. Pain 2020;161:1976–1982.

4. Loeser JD, Fordyce WE. Chronic pain. In: Carr JE, Dengerink HA (eds). Behavioral Science in the Practice of Medicine. New York: Elsevier, 1983:331–346.

5. De La Torre Canales G, Câmara-Souza MB, Muñoz Lora VRM, et al. Prevalence of psychosocial impairment in temporoman-dibular disorder patients: A systematic review. J Oral Rehabil 2018;45:881–889.

6. Poluha RL, De la Torre Canales G, Bonjardim LR, Conti PCR. Somatosensory and psychosocial profile of patients with painful temporomandibular joint clicking. J Oral Rehabil 2020;47:1346–1357.

7. Poluha RL, De la Torre Canales G, Bonjardim LR, Conti PCR. Clinical variables associated with the presence of articular pain in patients with temporomandibular joint clicking. Clin Oral Investig 2021;25:3633–3640.

8. Fillingim RB, Ohrbach R, Greenspan JD, et al. Psychological factors associated with development of TMD: The OPPERA prospective cohort study. J Pain 2013;14:75–90.

9. Schiffman E, Ohrbach R, Truelove E, et al. Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) for clinical and research applications: Recommendations of the International RDC/TMD Consortium Network* and Orofacial Pain Special Interest Group†. J Oral Facial Pain Headache 2014;28:6–27.

10. Ohrbach R. Assessment and further development of RDC/TMD Axis II biobehavioural instruments: a research programme progress report. J Oral Rehabil 2010;37:784–798.

11. De la Torre Canales G, Bonjardim LR, Poluha RL, Carvalho Soares FF, Guarda-Nardini L, Conti PR, et al. Correlation between physical and psychosocial findings in a population of temporomandibular disorder patients. Int J Prosthodont 2020;33:155–159.

12. Ohrbach R, Dworkin SF. The evolution of TMD diagnosis: Past, present, future. J Dent Res 2016;95:1093–1101.

13. Gil-Martínez A, Paris-Alemany A, López-de-Uralde-Villanueva I, La Touche R. Management of pain in patients with temporomandibular disorder (TMD): Challenges and solutions. J Pain Res 2018;16:571–587.

14. Kuzmanovic Pficer J, Dodic S, Lazic V, Trajkovic G, Milic N, Milicic B. Occlusal stabilization splint for patients with temporomandibular disorders: Meta-analysis of short and long term effects. PLoS One 2017;12:e0171296.

15. Costa YM, Porporatti AL, Stuginski-Barbosa J, Bonjardim LR, Conti PC. Additional effect of occlusal splints on the improvement of psychological aspects in temporomandibular disorder subjects: A randomized controlled trial. Arch Oral Biol 2015;60:738–744.

16. De la Torre Canales G, Manfredini D, Grillo CM, Guarda-Nardini L, Machado Gonçalves L, Rizzatti Barbosa CM. Therapeutic effectiveness of a combined counseling plus stabilization appliance treatment for myofascial pain of the jaw muscles: A pilot study. Cranio 2017;35:180–186.

17. Roldán-Barraza C, Janko S, Villanueva J, Araya I, Lauer HC. A systematic review and meta-analysis of usual treatment versus psychosocial interventions in the treatment of myofascial temporomandibular disorder pain. J Oral Facial Pain Headache 2014;28:205–222.

18. Nazeri M, Ghahrechahi HR, Pourzare A, et al. Role of anx-iety and depression in association with migraine and myofascial pain temporomandibular disorder. Indian J Dent Res 2018;29:583–587.

19. Matak I, Lackovic´ Z. Botulinum toxin A, brain and pain. Prog Neurobiol 2014;119–120:39–59.

20. De la Torre Canales G, Alvarez-Pinzon N, Muñoz-Lora VRM, et al. Efficacy and safety of botulinum toxin type A on persistent myofascial pain: A randomized clinical trial. Toxins (Basel) 2020;12:395.

21. Zhang H, Zhang H, Wei Y, Lian Y, Chen Y, Zheng Y. Treatment of chronic daily headache with comorbid anxiety and depression using botulinum toxin A: A prospective pilot study. Int J Neurosci 2017;127:285–290.

22. Ceylan D, Erer S, Zarifog˘u M, Türkes¸ N, Özkaya G. Evaluation of anxiety and depression scales and quality of LIFE in cervical dystonia patients on botulinum toxin therapy and their relatives. Neurol Sci 2019;40:725–731.

23. Weber A, Heger S, Sinkgraven R, Heckmann M, Elsner P, Rzany B. Psychosocial aspects of patients with focal hyperhidrosis. Marked reduction of social phobia, anxiety and depression and increased quality of life after treatment with botulinum toxin A. Br J Dermatol 2005;152:342–345.

24. Dong H, Fan S, Luo Y, Peng B. Botulinum toxin relieves anxiety and depression in patients with hemifacial spasm and blephar-ospasm. Neuropsychiatr Dis Treat 2018;15:33–36.

25. Patel AA, Lerner MZ, Blitzer A. IncobotulinumtoxinA injection for temporomandibular joint disorder. Ann Otol Rhinol Laryngol 2017;126:328–333.

26. Pereira FJ, Favilla EE, Dworkin SF, Huggins KH. Critérios de diagnóstico para pesquisa das desordens temporomandibulares RDC/TMD. International Network for Orofacial Pain and Related Disorders Methodology, 2002. https://ubwp.buffalo. edu/rdc-tmdinternational/tmd-assessmentdiagnosis/rdc-tmd/translations/. Accessed 7 October 2021.

27. John MT, Reissmann DR, Schierz O, Wassell RW. Oral healthrelated quality of life in patients with temporomandibular disorders. J Orofac Pain 2007;21:46–54.

28. Manfredini D, Winocur E, Ahlberg J, Guarda-Nardini L, Lobbezoo F. Psychosocial impairment in temporomandibular disorders patients. RDC/TMD axis II findings from a multi-centre study. J Dent 2010;38:765–772.

29. Canales GT, Guarda-Nardini L, Rizzatti-Barbosa CM, Conti PCR, Manfredini D. Distribution of depression, somatization and pain- related impairment in patients with chronic temporo-mandibular disorders. J Appl Oral Sci 2019;27:e20180210.

30. Ozdemir-Karatas M, Peker K, Balık A, Uysal O, Tuncer EB. Identifying potential predictors of painrelated disability in Turkish patients with chronic temporomandibular disorder pain. J Headache Pain 2013;14:17.

31. Lorduy KM, Liegey-Dougall A, Haggard R, Sanders CN, Gatchel RJ. The prevalence of comorbid symptoms of central sensitization syndrome among three different groups of temporomandibular disorder patients. Pain Pract 2013;13:604–613.

32. Greenspan JD, Slade GD, Bair E, et al. Identified pain sensitivity risk factors for chronic TMD: Descriptive data and empirically identified domains from the OPPERA case control study. J Pain 2011;12(suppl 11):T61–T74.

33. Campi LB, Jordani PC, Tenan HL, Camparis CM, Gonçalves DA. Painful temporomandibular disorders and central sensitization: Implications for management–a pilot study. Int J Oral Maxillofac Surg 2017;46:104–110.

34. Yap AU, Dworkin SF, Chua EK, List T, Tan KB, Tan HH. Prevalence of temporomandibular disorder subtypes, psychologic distress, and psychosocial dysfunction in Asian patients. J Orofac Pain 2003;17:21–28.

35. Manfredini D, Arveda N, Guarda-Nardini L, Segù M, Collesano V. Distribution of diagnoses in a population of patients with temporomandibular disorders. Oral Surg Oral Med Oral Pathol Oral Radiol 2012;114:35–41.

36. Muñoz-Lora VRM, Clemente-Napimoga JT, Ballassini H, Gomes-Macedo C, De la Torre Canales G, Rizzatti- Barbosa CM. Botulinum toxin type A reduces inflammatory hypernociception induced by arthritis in the temporomandibular joint of rats. Toxicon 2017;129: 52–57.

37. Matak I, Bach-Rojecky L, Filipovic´ B, Lackovic Z. Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience 2011;186:201–207.

38. Ernberg M, Hedenberg-Magnusson B, List T, Svensson P. Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: A randomized, controlled, double-blind multicenter study. Pain 2011;152:1988–1996.

39. Kurtoglu C, Gur OH, Kurkcu M, Sertdemir Y, Guler-Uysal F, Uysal H. Effect of botulinum toxin-A in myofascial pain patients with or without functional disc displacement. J Oral Maxillofac Surg 2008;66:1644–1651.

40. Xia JH, He CH, Zhang HF, et al. Botulinum toxin A in the treatment of trigeminal neuralgia. Int J Neurosci 2016;126:348–353.

41. Blumenfeld AM, Tepper SJ, Robbins LD, et al. Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety. J Neurol Neurosurg Psychiatry 2019;90:353–360.

42. Wollmer MA, de Boer C, Kalak N, et al. Facing depression with botulinum toxin: A randomized controlled trial. J Psychiatr Res 2012;46:574–581.

43. Finzi E, Rosenthal NE. Treatment of depression with onabotulinumtoxinA: A randomized, double-blind, placebo controlled trial. J Psychiatr Res 2014;52:1–6.

44. Magid M, Reichenberg JS, Poth PE, et al. Treatment of ma-jor depressive disorder using botulinum toxin A: A 24-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2014;75:837–844.

45. Hexsel D, Brum C, Siega C, et al. Evaluation of self-esteem and depression symptoms in depressed and nondepressed subjects treated with onabotulinumtoxinA for glabellar lines. Dermatol Surg 2013;39:1088–1096.

46. Makunts T, Wollmer MA, Abagyan R. Postmarketing safety surveillance data reveals antidepressant effects of botulinum toxin across various indications and injection sites. Sci Rep 2020;10:12851.

47. Otsuka T, Watanabe K, Hirano Y, et al. Effects of mandibular deviation on brain activation during clenching: An fMRI prelim-inary study. J Craniomandib Pract 2009;27:88–93.

48. Greven M, Otsuka T, Zutz L, Weber B, Elger C, Sato S. The amount of TMJ displacement correlates with brain activity. J Craniomandib Pract 2011;29:291–296.

49. Lotze M, Lucas C, Domin M, Kordass B. The cerebral representation of temporomandibular joint occlusion and its alternation by occlusal splints. Hum Brain Mapp 2012;33:2984–2993.

50. Ariji Y, Koyama S, Sakuma S, Nakayama M, Ariji E. Regional brain activity during jaw clenching with natural teeth and with occlusal splints: A preliminary functional MRI study. Cranio 2016;34:188–194.

51. Balanta-Melo J, Toro-Ibacache V, Kupczik K, Buvinic S. Mandibular bone loss after masticatory muscles intervention with botulinum toxin: An approach from basic research to clin-ical findings. Toxins 2019;11:84.

52. De la Torre Canales G, Poluha RL, Lora VM, et al. Botulinumtoxin type A applications for masticatory myofascial pain and trigeminal neuralgia: What is the evidence regarding adverse effects? Clin Oral Investig 2019;23:3411–3421.

53. Tuna SH, Celik OE, Ozturk O, et al. The effects of stabilization splint treatment on the volume of masseter muscle in sleep bruxism patients. Cranio 2018;36:286–293.

54. Dworkin SF, Sherman J, Mancl L, Ohrbach R, LeResche L,Truelove E. Reliability, validity, and clinical utility of the Research Diagnostic Criteria for Temporomandibular Disorders axis II scales: Depression, non-specific physical symptoms, and graded chronic pain. J Orofac Pain 2002;16:207–220.

55. Manfredini D, Ahlberg J, Winocur E, Guarda-Nardini L, Lobbezoo F. Correlation of RDC/TMD axis I diagnoses and axis II painrelated disability. A multicenter study. Clin Oral Investig 2011;15:749–756.

56. Truelove E, Pan W, Look JO, et al. The Research Diagnostic Criteria for Temporomandibular Disorders. III: Validity of Axis I diagnoses. J Orofac Pain 2010;24:35–47.